MeCP2 Gene Therapy Vector with Truncated 3'UTR for Toxicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Rett syndrome, caused by loss-of-function mutations in the MECP2 gene, have not been successful in achieving substantial therapeutic benefits due to challenges in targeting MeCP2 pathways and maintaining physiological protein levels, leading to limited brain transduction and potential toxicity.
Innovation Solution
Development of an instability-prone MeCP2 (iMecp2) transgene cassette that prevents supraphysiological MeCP2 protein levels through increased RNA destabilization and inefficient protein translation, using an AAV9 PHP.eB vector for intravenous delivery to symptomatic mice, achieving widespread and efficient gene transfer while maintaining safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Area of stationary object
If AAV9 vector is used for intravenous delivery of MeCP2 gene, then widespread brain transduction is achieved, but supraphysiological MeCP2 protein levels cause toxicity
Solution Approach 1:
The patent modifies the transgene cassette parameters by incorporating a truncated 3'UTR and specific Kozak sequence to alter translation efficiency and mRNA stability, thereby controlling protein expression levels to remain physiological despite widespread brain transduction
Solution Approach 2:
The design incorporates regulatory elements that provide feedback control on MeCP2 expression levels, preventing supraphysiological accumulation through controlled mRNA degradation and translation efficiency mechanisms
2Quantity of substance
If strong promoter is used to drive MeCP2 expression, then sufficient protein production is achieved, but RNA stability increases leading to supraphysiological levels
Solution Approach 1:
The patent truncates the 3'UTR to specific length ranges (50-300 bp, preferably 100-200 bp) to reduce RNA stability and control protein expression levels, balancing sufficient production with prevention of supraphysiological accumulation
Solution Approach 2:
The patent uses a strong promoter for sufficient protein production but deliberately limits the outcome by combining it with a truncated 3'UTR, achieving partial expression control rather than full activation of the strong promoter's potential
3Reliability
If MeCP2 gene therapy is administered to achieve therapeutic benefit, then neurological symptoms improve, but delivery challenges limit transduction efficiency
Solution Approach 1:
The patent uses AAV9 vector as an intermediary delivery system that facilitates efficient transduction of the MeCP2 gene across the blood-brain barrier, overcoming delivery challenges while maintaining controlled expression levels
Solution Approach 2:
The AAV9 vector provides multi-functionality by enabling both efficient delivery to widespread brain regions and controlled expression through the engineered transgene cassette with truncated 3'UTR and optimized Kozak sequence
Data Source
AI summary
A polynucleotide comprising a nucleotide sequence encoding methyl-CpG binding-protein 2 (MeCP2) operably linked to a strong promoter and a 3′-UTR, wherein the 3′-UTR is less than or equal to about 1000 bp in length.